Biochemistry, Genetics and Molecular Biology
Cooperation
100%
Metabotropic Glutamate Receptor 5
100%
Inverse Agonist
100%
Inositol Phosphate
100%
Animal Model
50%
Agonist
50%
Pharmacokinetics
50%
Synaptic Transmission
50%
Preclinical Study
50%
Calcium Cell Level
50%
Calcium Mobilization
50%
Allosteric Site
50%
Metabotropic Glutamate Receptor
50%
Metabotropic Receptor
50%
Synapse
50%
Maximal Transitional Entropy Production
50%
Tranquilizing Activity
50%
Neuroscience
In Vivo
100%
Central Nervous System
100%
Metabotropic Glutamate Receptor 5
100%
Inositol Phosphate
66%
Inverse Agonist
66%
Alzheimer's Disease
33%
Agonist
33%
Parkinson's Disease
33%
L-DOPA
33%
Adverse Effect
33%
Synapse
33%
Synaptic Transmission
33%
Metabotropic Glutamate Receptor
33%
Metabotropic Receptor
33%
Dyskinesia
33%
Allosteric Site
33%
Schaffer Collateral
33%
Fragile X Syndrome
33%
MTEP
33%
Pharmacokinetics
33%
Keyphrases
Metabotropic Glutamate Receptor
100%
Metabotropic Glutamate Receptor 5 (mGluR5)
100%
Negative Allosteric Modulator
100%
In Vivo Efficacy
100%
Occupancy
36%
Central Nervous System
27%
Agonist Activity
18%
Inverse Agonist
18%
Inositol Phosphate Accumulation
18%
Extracellular Signal-regulated Kinase 1/2
9%
Alzheimer's Disease
9%
Phosphorylation
9%
Dose Effect
9%
Adverse Effects
9%
Parkinson's Disease
9%
Rodents
9%
Synaptic Transmission
9%
Pharmacokinetic Profile
9%
Therapeutic Use
9%
Addiction
9%
Picolinamide
9%
Systemic Administration
9%
Levodopa-induced Dyskinesia
9%
Allosteric Site
9%
Intracellular Calcium Mobilization
9%
Maximal Effect
9%
Anxiolytic Activity
9%
Cooperativity
9%
Brain Penetration
9%
Fragile X Syndrome
9%
Phosphatase Inhibition
9%
Effect Measure
9%
3-fluorophenyl
9%
Ethynyl
9%
Schaffer collateral-CA1 Synapses
9%
Functional Bias
9%
Negative Cooperativity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Allosteric Modulator
100%
Metabotropic Receptor 5
100%
Inositol Phosphate
20%
2 Methyl 6 (Phenylethynyl)pyridine
20%
Inverse Agonist
20%
Alzheimer's Disease
10%
Metabotropic Receptor
10%
Adverse Event
10%
Clinical Study
10%
Preclinical Study
10%
Parkinson's Disease
10%
Therapeutic Use
10%
Picolinamide
10%
Systemic Administration
10%
Levodopa-Induced Dyskinesia
10%
MTEP
10%
Fragile X Syndrome
10%
Anxiolytic Activity
10%
Pharmacokinetics
10%